Abstract
Purpose
The combination of morphine and gabapentin seems promising for the treatment of postoperative and neuropathic pain. Despite the well characterised pharmacodynamic interaction, little is known about possible pharmacokinetic interactions. The aim of this study was to evaluate whether co-administration of the two drugs leads to modifications of their pharmacokinetic profiles.
Methods
The pharmacokinetics of morphine, morphine-3-glucuronide and gabapentin were characterised in rats following subcutaneous injections of morphine, gabapentin or their combination. Non-linear mixed effects modelling was applied to describe the pharmacokinetics of the compounds and possible interactions.
Results
The plasma-concentration-time profiles of morphine and gabapentin were best described using a three- and a one-compartment disposition model respectively. Dose dependencies were found for morphine absorption rate and gabapentin bioavailability. Enterohepatic circulation of morphine-3-glucuronide was modelled using an oscillatory model. The combination did not lead to pharmacokinetic interactions for morphine or gabapentin but resulted in an estimated ~33% diminished morphine-3-glucuronide formation.
Conclusions
The finding of a lack of pharmacokinetic interaction strengthens the notion that the combination of the two drugs leads to better efficacy in pain treatment due to interaction at the pharmacodynamic level. The interaction found between gabapentin and morphine-3-glucuronide, the latter being inactive, might not have any clinical relevance.
Similar content being viewed by others
Abbreviations
- EHC:
-
Enterohepatic circulation
- M3G:
-
Morphine-3-Glucuronide
- M6G:
-
Morphine-6-Glucuronide
- MS/MS:
-
Tandem mass spectrometry
- NONMEM:
-
Non-linear mixed effects modelling
- OFV:
-
Objective function value
- UPLC:
-
Ultra-high-performance liquid chromatography
- VPC:
-
Visual predictive check
References
Dahl JB, Mathiesen O, Kehlet H. An expert opinion on postoperative pain management, with special reference to new developments. Expert Opin Pharmacother. 2010;11(15):2459–70.
Baron R, Binder A, Wasner G. Neuropathic pain: diagnosis, pathophysiological mechanisms, and treatment. Lancet Neurol. 2010. p. 807–19.
McNicol ED, Midbari A, Eisenberg E. Opioids for neuropathic pain. Cochrane database Syst Rev. 2013;8.
Taylor CP. Mechanisms of analgesia by gabapentin and pregabalin-calcium channel alpha2-delta [Cava2-δ] ligands. Pain Int Assoc Stud Pain. 2009;142(1-2):13–6.
Rose MA, Kam PCA. Gabapentin: pharmacology and its use in pain management. Anaesthesia. 2002. p. 451–62.
Bennett M, Simpson K. Gabapentin in the treatment of neuropathic pain. Palliat Med. 2004;18:5–11.
Rosner H, Rubin L, Kestenbaum A. Gabapentin adjunctive therapy in neuropathic pain states. Clin J Pain. 1996. p. 56–8.
Lunn TH, Husted H, Laursen MB, Hansen LT, Kehlet H. Analgesic and sedative effects of perioperative gabapentin in total knee arthroplasty. A randomized, double-blind, placebo-controlled, dose-finding study. Pain. 2015;156:1.
Kong VKF, Irwin MG. Gabapentin: a multimodal perioperative drug? Br J Anaesth. 2007;99(6):775–86.
Mathiesen O, Møiniche S, Dahl JB. Gabapentin and postoperative pain: a qualitative and quantitative systematic review, with focus on procedure. BMC Anesthesiol. 2007;7:6.
Shimoyama M, Shimoyama N, Inturrisi CE, Elliott KJ. Gabapentin enhances the antinociceptive effects of spinal morphine in the rat tail-flick test. Pain. 1997;72(3):375–82.
Matthews E, Dickenson A. A combination of gabapentin and morphine mediates enhanced inhibitory effects on dorsal horn neuronal responses in a rat model of neuropathy. Anesthesiology. 2002;96(3):633–40.
Smiley MM, Lu Y, Vera-Portocarrero LP, Zidan A, Westlund KN. Intrathecal gabapentin enhances the analgesic effects of subtherapeutic dose morphine in a rat experimental pancreatitis model. Anesthesiology. 2004;101(3):759–65.
Papathanasiou T, Juul RV, Heegaard A-M, Kreilgaard M, Lund TM. Co-administration of morphine and gabapentin leads to dose dependent synergistic effects in a rat model of postoperative pain. Eur J Pharm Sci. 2016;82:97–105.
Keskinbora K, Pekel AF, Aydinli I. Gabapentin and an opioid combination versus opioid alone for the management of neuropathic cancer pain: a randomized open trial. J Pain Symptom Manag. 2007;34:183–9.
Dirks J, Fredensborg BB, Christensen D, Fomsgaard JS, Flyger H, Dahl JB. A randomized study of the effects of single-dose gabapentin versus placebo on postoperative pain and morphine consumption after mastectomy. 2002;97(22000947):560–4.
Gilron I. Gabapentin and pregabalin for chronic neuropathic and early postsurgical pain: current evidence and future directions. Curr Opin Anaesthesiol. 2007;20:456–72.
Gilron I, Bailey J, Tu D, Tesfaye S, Selvarajah D. Morphine, gabapentin, or their combination for neuropathic pain. N Engl J Med. 2005;352(25):2650–1.
Ouellet DM, Pollack GM. Biliary excretion and enterohepatic recirculation of morphine-3-glucuronide in rats. Drug Metab Dispos. 1995;23(4):478–84.
De la O-Arciniega M, Díaz-Reval MI, Cortés-Arroyo AR, Domínguez-Ramírez AM, López-Muñoz FJ. Anti-nociceptive synergism of morphine and gabapentin in neuropathic pain induced by chronic constriction injury. Pharmacol Biochem Behav. 2009;92(3):457–64.
Urban TJ, Brown C, Castro RA, Shah N, Mercer R, Huang Y, et al. Effects of genetic variation in the novel organic cation transporter, OCTN1, on the renal clearance of gabapentin. Clin Pharmacol Ther. 2008;83(3):416–21.
Keizer RJ, Karlsson MO, Hooker A. Modeling and simulation workbench for NONMEM: tutorial on Pirana, PsN, and Xpose. CPT Pharmacometrics Syst Pharmacol. 2013;2(November 2012):e50.
Sverrisdóttir E, Lund TM, Olesen AE, Drewes AM, Christrup LL, Kreilgaard M. A review of morphine and morphine-6-glucuronide’s pharmacokinetic-pharmacodynamic relationships in experimental and clinical pain. Eur J Pharm Sci. 2015;74:45–62.
Beal S, Sheiner L, Boeckmann A, Bauer R. NONMEM user’s guides. (1989-2009). Icon Dev Solut Ellicott City, MD, USA, 2009.
Team R. R Development Core Team. R A Lang Environ Stat Comput. 2013.
Wickham H. ggplot2. Wiley Interdiscip Rev Comput Stat. 2011;3(2):180–5.
Bergstrand M, Hooker AC, Wallin JE, Karlsson MO. Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J. 2011;13(2):143–51.
Wajima T, Yano Y, Oguma T. A pharmacokinetic model for analysis of drug disposition profiles undergoing enterohepatic circulation. J Pharm Pharmacol. 2002;54:929–34.
Lehr T, Staab A, Tillmann C, Trommeshauser D, Schaefer HG, Kloft C. A quantitative enterohepatic circulation model: development and evaluation with tesofensine and meloxicam. Clin Pharmacokinet. 2009;48(8):529–42.
Bouw MR, Gårdmark M, Hammarlund-Udenaes M. Pharmacokinetic-pharmacodynamic modelling of morphine transport across the blood-brain barrier as a cause of the antinociceptive effect delay in rats--a microdialysis study. Pharm Res. 2000;17(10):1220–7.
Eckhardt K, Ammon S, Hofmann U, Riebe A, Gugeler N, Mikus G. Gabapentin enhances the analgesic effect of morphine in healthy volunteers. Anesth Analg. 2000;91(1):185–91.
Roberts MS, Magnusson BM, Burczynski FJ, Weiss M. Enterohepatic circulation: physiological, pharmacokinetic and clinical implications. Clin Pharmacokinet. 2002;41(10):751–90.
Huntjens DRH, Strougo A, Chain A, Metcalf A, Summerfield S, Spalding DJM, et al. Population pharmacokinetic modelling of the enterohepatic recirculation of diclofenac and rofecoxib in rats. Br J Pharmacol. 2008;153(5):1072–84.
Taneja A, Nyberg J, de Lange ECM, Danhof M, Della Pasqua O. Application of ED-optimality to screening experiments for analgesic compounds in an experimental model of neuropathic pain. J Pharmacokinet Pharmacodyn. 2012;39(6):673–81.
Larsen MS, Keizer R, Munro G, Mørk A, Holm R, Savic R, et al. Pharmacokinetic/Pharmacodynamic relationship of gabapentin in a CFA-induced inflammatory hyperalgesia rat model. Pharm Res. 2016;1–11.
Ekblom M. Pharmacokinetics and pharmacodynamics of morphine-3-glucuronide in rats and its influence on the antinociceptive effect of morphine. Drug Dispos. 1993;14:1–11.
Dahlström BE, Paalzow LK. Pharmacokinetic interpretation of the enterohepatic recirculation and first-pass elimination of morphine in the rat. J Pharmacokinet Biopharm. 1978;6(6):505–19.
Mazoit JX, Butscher K, Samii K. Morphine in postoperative patients: pharmacokinetics and pharmacodynamics of metabolites. Anesth Analg. 2007;105:70–8.
Chen C, Upward J, Arumugham T, Stier B, Davy M. Gabapentin enacarbil and morphine administered in combination versus alone: a double-blind, randomized, pharmacokinetic, and tolerability comparison. Clin Ther. 2015;37(2):349–57.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Papathanasiou, T., Juul, R.V., Gabel-Jensen, C. et al. Population Pharmacokinetic Modelling of Morphine, Gabapentin and their Combination in the Rat. Pharm Res 33, 2630–2643 (2016). https://doi.org/10.1007/s11095-016-1988-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11095-016-1988-z